Isavuconazonium is a triazole antifungal used for the treatment of invasive aspergillosis and mucormycosis. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations.
- Mechanism
- Curator reviewed · 1 reference
Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane, by inhibiting cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase (Erg11p). This enzyme is responsible for the conversion of lanosterol to ergosterol. An accumulation of methylated sterol precursors and a depletion of ergosterol within the fungal cell membrane weaken the membrane structure and function. Mammalian cell demethylation is less sensitive to isavuconazole inhibition.
- Primary indication
- Isavuconazonium is indicated for the treatment of invasive aspergillosis and mucormycosis in adults and pediatric patients 1 year of age and older in capsule form and adults and pediatric patients 6 years of age and...Curator reviewed · 4 structured indications
- Formula / weight
- C35H35F2N8O5S · 717.77 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2015
- Code names
- BAL-8557
- Brand names
Resolves to
RSWOJTICKMKTER-QXLBVTBOSA-NSMILES[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Isavuconazonium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account